[S2E10] Vincent Catalano: GLP-1 Forever? Why Taking a Drug for Life Might Not Be the Problem

Episode notes

The headlines will tell you that stopping a GLP-1 means gaining the weight back. And they're right. A study of 77,000 patients confirms it: stop the drug, and the weight returns within a year to a year and a half. But Vincent Catalano isn't sure that's the problem everyone is making it out to be. In this solo episode, Vincent connects his own 23-year experience taking atorvastatin to manage cholesterol with the growing reality that some people will take GLP-1s indefinitely to manage their weight. The same logic applies: if the drug works, if the price is manageable, and if it keeps a larger health problem in check, why is lifetime use a bad thing? With pill-form GLP-1s dropping to around $200 a month and prices expected to fall further, Vincent walks through the math: $200 a month is two dinners out. For someone managing obesity and its downstream health risks, that may be one of the most cost-effective decisions available. About Vincent Catalano: Vincent Catalano brings over 23 years of employee benefits experience as an independent consultant and host of The CLEARly Beneficial Podcast.

Related episodes across the Index

Other episodes covering the same guests and topics, from across The B2B Podcast Index.

• Targeting the Root Causes of Metabolic Disease w/ Bob Geho, Founder & CEO, DiasomeCareTalk: Healthcare. Unfiltered. · on GLP-194 / 100
• How Deepak Datta Turned Medical Tourism Into a Global Healthcare BusinessMarket Movers · on Ozempic65 / 100
• The GLP-1 Economy: How New Prescriptions Are Reshaping MarketsThe Important Part: Investing with Liz Thomas · on Ozempic63 / 100
• The Bottom Line Catch Up | Ep. 1 | Tax Season, Transitions, and the Peptide WaveThe Bottom Line Pharmacy Podcast · on GLP-150 / 100
• Mr. Beast’s Amazon Prime Show, Macy’s Running UGC Ada, & More | Whale Informed #008Whale Informed by Triple Whale · on Ozempic43 / 100
• Office Hours | Made From MistakesOffice Hours with David Meltzer · on Ozempic41 / 100

• [S2E24] The Kaiser/Non-Kaiser Death Spiral: What Employers Need to Know61 / 100
• [S2E22] HR & CFO’s: Before Benefits Decision Season Begins, Start Here.52 / 100
• [S2E21] From Cannes: The Rest of the World Posts the Price. America Won't.39 / 100
• [S2E20] Vincent Catalano: Let’s Not Normalize Medical Debt49 / 100
• [S2E19] Healthcare Big Ideas86 / 100